Page 132 - 83_02

alcoholic Fatty Liver Disease. Frontiers in pharmacol
2017;8:3.
25. O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E,
Krejsa CM, Slaughter MR, et al. High concordance of
drug-induced human hepatotoxicity with in vitro
cytotoxicity measured in a novel cell-based model
using high content screening. Archives of toxicology
2006;80:580-604.
26. Amacher DE. Strategies for the early detection of
drug-induced hepatic steatosis in preclinical drug
safety evaluation studies. Toxicology 2011;279:10-18.
27. Donato MT, Martinez-Romero A, Jimenez N, Negro
A, Herrera G, Castell JV, et al. Cytometric analysis
for drug-induced steatosis in HepG2 cells. Chemico-
biological interactions 2009;181:417-423.
28. Donato MT, Tolosa L, Jimenez N, Castell JV, Gomez-
Lechon MJ. High-content imaging technology for the
evaluation of drug-induced steatosis using a
multiparametric cell-based assay. J Biomol Screen
2012;17:394-400.
29. Bell LN, Chalasani N. Epidemiology of idiosyncratic
drug-induced liver injury. Seminars in liver disease
2009;29:337-347.
30. Rembold CM. Combination therapy of dyslipidemia in
non-insulin-dependent diabetes mellitus and the
metabolic syndrome. Current diabetes reports
2004;4:330-334.
31. Kim-Mitsuyama S. Combination therapy of
angiotensin receptor blocker with statin or
thiazolidinediones as promising therapeutic strategy
for metabolic syndrome and atherosclerosis.
Hypertension research 2009;32:639-640.
32. Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic
drugs. Clinics in liver disease 2003;7:415-433.
33. Chalasani N. Statins and hepatotoxicity: focus on
patients with fatty liver. Hepatology 2005;41:690-695.
34. Ghali P, Lindor KD. Hepatotoxicity of drugs used for
treatment of obesity and its comorbidities. Seminars in
liver disease 2004;24:389-397.
35. Masubuchi Y. Metabolic and non-metabolic factors
determining troglitazone hepatotoxicity: a review.
Drug metabolism and pharmacokinetics 2006;21:347-
356.
36. Dourakis SP, Tzemanakis E, Sinani C, Kafiri G,
Hadziyannis SJ. Gliclazide-induced acute hepatitis.
European journal of gastroenterology & hepatology
2000;12:119-121.
37. Da Silva GH, Alves AV, Duques P, Seva-Pereira T,
Soares EC, Escanhoela CA. Acute hepatotoxicity
caused by enalapril: a case report. Journal of
gastrointestinal and liver diseases 2010;19:187-190.
38. Wang XW, Heegaard NH, Orum H. MicroRNAs in
liver disease. Gastroenterology 2012;142:1431-1443.
39. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard
CC, Gibson DF, et al. Argonaute2 complexes carry a
population of circulating microRNAs independent of
292
Ramiro Jover Atienza
vesicles in human plasma. Proceedings of the National
Academy of Sciences of the United States of America
2011;108:5003-5008.
40. Boon RA, Vickers KC. Intercellular transport of
microRNAs. Arteriosclerosis, thrombosis, and
vascular biology 2013;33:186-192.
41. Vickers KC, Palmisano BT, Shoucri BM, Shamburek
RD, Remaley AT. MicroRNAs are transported in
plasma and delivered to recipient cells by high-density
lipoproteins. Nature cell biology 2011;13:423-433.
42. Lee WM. Drug-induced hepatotoxicity. N Engl J Med
2003;349:474-485.
43. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C,
Guilleminet C, et al. Incidence of drug-induced
hepatic injuries: a French population-based study.
Hepatology 2002;36:451-455.
44. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran
RB, Olafsson S. Incidence, presentation, and
outcomes in patients with drug-induced liver injury in
the general population of Iceland. Gastroenterology
2013;144:1419-1425, 1425 e1411-1413; quiz e1419-
1420.
45. Friis H, Andreasen PB. Drug-induced hepatic injury:
an analysis of 1100 cases reported to the Danish
Committee on Adverse Drug Reactions between 1978
and 1987. J Intern Med 1992;232:133-138.
46. Lewis JH. Drug-induced liver disease. Med Clin North
Am 2000;84:1275-1311, x.
47. Lucena MI, Andrade RJ, Kaplowitz N, Garcia-Cortes
M, Fernandez MC, Romero-Gomez M, et al.
Phenotypic characterization of idiosyncratic drug-
induced liver injury: the influence of age and sex.
Hepatology 2009;49:2001-2009.
48. Yang K, Kock K, Sedykh A, Tropsha A, Brouwer KL.
An updated review on drug-induced cholestasis:
mechanisms and investigation of physicochemical
properties and pharmacokinetic parameters. J Pharm
Sci 2013;102:3037-3057.
49. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-
induced cholestasis. Hepatology 2011;53:1377-1387.
50. Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz
B, Borraz Y, Pachkoria K, et al. Outcome of acute
idiosyncratic drug-induced liver injury: Long-term
follow-up in a hepatotoxicity registry. Hepatology
2006;44:1581-1588.
51. Fontana RJ, Hayashi PH, Barnhart H, Kleiner DE,
Reddy KR, Chalasani N, et al. Persistent liver
biochemistry abnormalities are more common in older
patients and those with cholestatic drug induced liver
injury. Am J Gastroenterol 2015;110:1450-1459.
52. Diaz FC, Saez-Gonzalez E, Benlloch S, Alvarez-
Sotomayor D, Conde I, Polo B, et al. Albumin dialysis
with MARS for the treatment of anabolic steroid-
induced cholestasis. Ann Hepatol 2016;15:939-943.
53. Wittebole X, Hantson P. Use of the molecular
adsorbent recirculating system (MARS) for the
@Real Academia Nacional de Farmacia. Spain